Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Abstract

Objective. To analyse the efficacy and tolerance of infliximab in refractory Takayasu arteritis (TA).

Methods. French multicentre retrospective study that included patients with TA. Clinical disease activity was defined as new vascular and/or constitutional signs.

Results. Fifteen patients with TA [median age 41 (range 17–61) years; 13 women] were included. At initiation of infliximab therapy, 14 patients were treated with CSs [prednisone; median dose 20 (range 5–35) mg/day], MTX (n = 7) or AZA (n = 4). Infliximab was used at median 5 (range 3–5) mg/kg at a median of every 6 (range 4–8) weeks. A partial or good overall response was noted in 13 (87%) of the 15 cases, 10 (77%) of the 13 cases and 8 (73%) of the 11 cases at 3, 6 and 12 months, respectively. Clinical and biological activities significantly decreased within 3 months (from 11 at baseline to 4 patients at 12 months; P < 0.05), and similarly for CS dose [from median 20 (range 5–35) mg/day at baseline to median 6 (range 2.5–30) mg/day at 12 months; P < 0.05]. Only one patient was still steroid-dependent at 12 months (vs 8 cases before infliximab). CRP regressed from a median 30 (range 4–70) mg/l to 5 (range 0–57) mg/l and 6 (0–50) mg/l at 3 and 6 months, respectively (P < 0.05). Side effects were two infusion-related reactions, one pulmonary tuberculosis, one severe bacterial infection and EBV reactivation.

Conclusion. This study confirms the interest of infliximab in terms of clinical and biological response, as well as the steroid-sparing effect in TA.

Takayasu arteritis, treatment, infliximab
© The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [email protected]
Topic:
Issue Section:
Clinical Science
You do not currently have access to this article.
Download all slides

Comments

0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.